Oppenheimer analyst Leland Gershell maintained a Buy rating on CalciMedica (CALC – Research Report) today and set a price target of $14.00. The company’s shares closed yesterday at $4.34.
According to TipRanks, Gershell is a 3-star analyst with an average return of 2.3% and a 36.63% success rate. Gershell covers the Healthcare sector, focusing on stocks such as Crinetics Pharmaceuticals, Catalyst Pharma, and Viridian Therapeutics.
The word on The Street in general, suggests a Strong Buy analyst consensus rating for CalciMedica with a $18.67 average price target, representing a 330.18% upside. In a report released yesterday, H.C. Wainwright also reiterated a Buy rating on the stock with a $20.00 price target.
See the top stocks recommended by analysts >>
The company has a one-year high of $8.59 and a one-year low of $1.00. Currently, CalciMedica has an average volume of 18.18K.
Based on the recent corporate insider activity of 61 insiders, corporate insider sentiment is positive on the stock. This means that over the past quarter there has been an increase of insiders buying their shares of CALC in relation to earlier this year.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
CalciMedica (CALC) Company Description:
Graybug Vision Inc is a clinical-stage biopharmaceutical company focused on developing transformative medicines for the treatment of diseases of the retina and optic nerve.
Read More on CALC:
